BA
BHVN

Bridgewater Associates’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bridgewater Associates’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,232
Closed -$640K – 953
2022
Q3 		$640K Sell
4,232
-2,076
-33% -$308K ﹤0.01% 753
2022
Q2 		$919K Buy
6,308
+408
+7% +$52.1K ﹤0.01% 799
2022
Q1 		$700K Buy
5,900
+1,782
+43% +$222K ﹤0.01% 846
2021
Q4 		$568K Buy
+4,118
New +$524K ﹤0.01% 635

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Bridgewater Associates's BHVN Position: Q4 2022 in Review

Bridgewater Associates sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 4,232 shares — an estimated $640K sold.

Bridgewater Associates first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $919K in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Bridgewater Associates reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Bridgewater Associates sold 4,232 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $640K.
  • Bridgewater Associates first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • Bridgewater Associates's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $919K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Bridgewater Associates's 13F filing for Q4 2022, filed 13 Feb 2023.